Unicycive Therapeutics, Inc.: RA CAPITAL MANAGEMENT, L.P. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
RA Capital Management, L.P. amended its Schedule 13G filing for Unicycive Therapeutics, Inc., disclosing its updated beneficial ownership stake in the company under SEC accession 0001346824-26-000297. The filing reflects the investment firm's current position in the clinical-stage biopharmaceutical company. The amendment matters because 13G updates signal shifts in institutional ownership that can influence investor sentiment around small-cap biotech names. The specific share count and percentage change were not detailed in the filing summary. Investors will watch for further 13G or 13D amendments to gauge whether RA Capital is accumulating or trimming its position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
RA Capital Management, L.P., Unicycive Therapeutics, Inc.